Skip to main content
Journal cover image

Intimal hyperplasia, saphenous vein graft disease, and clinical outcomes: Insights from the CTSN VEST randomized trial.

Publication ,  Journal Article
Goldstein, DJ; Chang, HL; Mack, MJ; Voisine, P; Gammie, JS; Marks, ME; Iribarne, A; Vengrenyuk, Y; Raymond, S; Taylor, BS; Dagenais, F ...
Published in: J Thorac Cardiovasc Surg
May 2024

BACKGROUND: Diffuse intimal hyperplasia and graft irregularity adversely affect the long-term patency of saphenous vein grafts (SVGs) and clinical outcomes of patients undergoing coronary artery bypass grafting (CABG). The VEST trial evaluated the efficacy of external graft support in limiting the development of intimal hyperplasia (IH) at 1 year postsurgery. In the present secondary analysis, we explored the associations between graft disease and IH and clinical events. We also examined risk factors for early graft occlusion. METHODS: VEST is a within-patient randomized, multicenter trial that enrolled 224 patients with multivessel coronary disease undergoing CABG surgery, of whom 203 were evaluated by 1 year postsurgery. Intimal hyperplasia, lumen uniformity, graft stenosis, and graft perfusion were measured by intravascular ultrasound and angiography. Major cardiac and cerebrovascular events (MACCE; including death, myocardial infarction, stroke, and revascularization) were recorded over a median follow-up of 3 years. RESULTS: Worse lumen uniformity, greater stenosis, and worse graft perfusion were associated with higher IH values and an increased incidence of clinical events. Consistent with previous findings, we identified endoscopic vein harvesting, female sex, and transit time flow measurement of pulsatility index and flow as risk factors for SVG occlusion during the first year postsurgery. CONCLUSIONS: In this secondary analysis of the VEST trial, we observed an association between intimal hyperplasia area and clinical measures of SVG disease at 1 year postsurgery. More severe SVG disease and larger areas of IH were associated with a higher incidence of 3-year MACCE. Ongoing follow-up to 5 years will further elucidate the impact of SVG disease on long-term clinical outcomes of CABG.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Thorac Cardiovasc Surg

DOI

EISSN

1097-685X

Publication Date

May 2024

Volume

167

Issue

5

Start / End Page

1782 / 1792.e5

Location

United States

Related Subject Headings

  • Vascular Patency
  • Treatment Outcome
  • Saphenous Vein
  • Respiratory System
  • Male
  • Hyperplasia
  • Humans
  • Graft Occlusion, Vascular
  • Female
  • Coronary Artery Bypass
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Goldstein, D. J., Chang, H. L., Mack, M. J., Voisine, P., Gammie, J. S., Marks, M. E., … Bagiella, E. (2024). Intimal hyperplasia, saphenous vein graft disease, and clinical outcomes: Insights from the CTSN VEST randomized trial. J Thorac Cardiovasc Surg, 167(5), 1782-1792.e5. https://doi.org/10.1016/j.jtcvs.2022.10.034
Goldstein, Daniel J., Helena L. Chang, Michael J. Mack, Pierre Voisine, James S. Gammie, Mary E. Marks, Alexander Iribarne, et al. “Intimal hyperplasia, saphenous vein graft disease, and clinical outcomes: Insights from the CTSN VEST randomized trial.J Thorac Cardiovasc Surg 167, no. 5 (May 2024): 1782-1792.e5. https://doi.org/10.1016/j.jtcvs.2022.10.034.
Goldstein DJ, Chang HL, Mack MJ, Voisine P, Gammie JS, Marks ME, et al. Intimal hyperplasia, saphenous vein graft disease, and clinical outcomes: Insights from the CTSN VEST randomized trial. J Thorac Cardiovasc Surg. 2024 May;167(5):1782-1792.e5.
Goldstein, Daniel J., et al. “Intimal hyperplasia, saphenous vein graft disease, and clinical outcomes: Insights from the CTSN VEST randomized trial.J Thorac Cardiovasc Surg, vol. 167, no. 5, May 2024, pp. 1782-1792.e5. Pubmed, doi:10.1016/j.jtcvs.2022.10.034.
Goldstein DJ, Chang HL, Mack MJ, Voisine P, Gammie JS, Marks ME, Iribarne A, Vengrenyuk Y, Raymond S, Taylor BS, Dagenais F, Ailawadi G, Chu MWA, DiMaio JM, Narula J, Moquete EG, O’Sullivan K, Williams JB, Crestanello JA, Scavo V, Puskas JD, Acker MA, Gillinov M, Gelijns AC, O’Gara PT, Moskowitz AJ, Alexander JH, Bagiella E. Intimal hyperplasia, saphenous vein graft disease, and clinical outcomes: Insights from the CTSN VEST randomized trial. J Thorac Cardiovasc Surg. 2024 May;167(5):1782-1792.e5.
Journal cover image

Published In

J Thorac Cardiovasc Surg

DOI

EISSN

1097-685X

Publication Date

May 2024

Volume

167

Issue

5

Start / End Page

1782 / 1792.e5

Location

United States

Related Subject Headings

  • Vascular Patency
  • Treatment Outcome
  • Saphenous Vein
  • Respiratory System
  • Male
  • Hyperplasia
  • Humans
  • Graft Occlusion, Vascular
  • Female
  • Coronary Artery Bypass